Hegde Megha, Raj Saurav, Tikadar Dhananjay, Nyamagoud Sanatkumar B
Department of Pharmacy Practice, KLE College of Pharmacy, Hubli, Karnataka.
Monaldi Arch Chest Dis. 2024 Dec 31;94(4). doi: 10.4081/monaldi.2023.2793. Epub 2023 Dec 1.
In India, a robust vaccine pharmacovigilance system is essential to the effective implementation of COVID-19 immunization programs, ensuring the safety and efficacy of the administered vaccines. The National Expert Group on Vaccine Administration for COVID-19 and the Pharmacovigilance Programme of India have played vital roles in monitoring and analyzing adverse events following immunization (AEFIs). These tools have made it easier to gather, assess, and report information about different adverse drug reactions connected to COVID-19 vaccines. However, there are several issues with India's vaccination pharmacovigilance, including underreporting and sluggish data gathering. To improve the efficiency of the pharmacovigilance system, it is crucial to address these issues and encourage active reporting by healthcare professionals and the general public. This insightful review article serves as a critical resource for shedding light on India's vaccine pharmacovigilance efforts throughout the COVID-19 vaccination drive. It also elucidates how these efforts are pivotal in bolstering public confidence in vaccines. The comprehensive coverage of reported AEFIs not only showcases the commitment to vaccine safety but also helps healthcare professionals and policymakers make informed decisions to enhance the overall vaccination program.
在印度，一个强大的疫苗药物警戒系统对于有效实施新冠疫苗接种计划、确保所接种疫苗的安全性和有效性至关重要。新冠疫苗接种国家专家小组和印度药物警戒计划在监测和分析免疫后不良事件（AEFI）方面发挥了重要作用。这些工具使收集、评估和报告与新冠疫苗相关的不同药物不良反应信息变得更加容易。然而，印度疫苗接种药物警戒存在若干问题，包括报告不足和数据收集迟缓。为提高药物警戒系统的效率，解决这些问题并鼓励医护人员和公众积极报告至关重要。这篇见解深刻的综述文章是揭示印度在新冠疫苗接种运动期间疫苗药物警戒工作的重要资源。它还阐明了这些努力对于增强公众对疫苗的信心如何至关重要。对报告的AEFI的全面涵盖不仅展示了对疫苗安全的承诺，也有助于医护人员和政策制定者做出明智决策，以加强整体疫苗接种计划。
